GSK Predicts China, Emerging Markets Recovery
This article was originally published in PharmAsia News
Executive Summary
GSK saw a decline in its sales in emerging markets last year, with the fall accelerating in the fourth quarter and affected mainly by an ongoing transitional period at its China business.